Keros Therapeutics (NASDAQ:KROS) Earns Buy Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a research report released on Tuesday, Benzinga reports. The brokerage currently has a $100.00 price target on the stock. Other analysts have also recently issued research reports about the stock. Truist Financial reissued a buy rating and issued a […]
More Stories
Financial Analysis: WEX (NYSE:WEX) versus Sezzle (NASDAQ:SEZL)
WEX (NYSE:WEX – Get Free Report) and Sezzle (NASDAQ:SEZL – Get Free Report) are both business services companies, but which...
Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 11,958 Shares of Stock
Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc bought 11,958 shares of the business’s stock in a...
Enel SpA (OTCMKTS:ENLAY) Short Interest Up 296.5% in December
Enel SpA (OTCMKTS:ENLAY – Get Free Report) saw a large increase in short interest in the month of December. As...
Carlyle Secured Lending, Inc. 8.20% Notes due 2028 (NASDAQ:CGBDL) Short Interest Update
Carlyle Secured Lending, Inc. 8.20% Notes due 2028 (NASDAQ:CGBDL – Get Free Report) was the target of a large growth...
WisdomTree Emerging Markets Quality Dividend Growth Fund (NASDAQ:DGRE) Short Interest Down 57.0% in December
WisdomTree Emerging Markets Quality Dividend Growth Fund (NASDAQ:DGRE – Get Free Report) was the target of a significant drop in...
ProShares Nasdaq-100 High Income ETF (NASDAQ:IQQQ) Short Interest Down 55.0% in December
ProShares Nasdaq-100 High Income ETF (NASDAQ:IQQQ – Get Free Report) was the target of a significant decline in short interest...